
Oxytocin - a naturally occurring hormone, known as the cuddle chemical, improves social cognition in only those who are less proficient socially, claim researchers at Mount Sinai School of Medicine.
The scientists wanted to determine if oxytocin, popularly dubbed the "hormone of love," could have widespread benefit in making us more understanding of others.
Advertisement
They conducted a randomized, double-blind, placebo-controlled, cross-over challenge, giving 27 healthy adult men oxytocin or a placebo delivered nasally.
Participants then performed an empathic accuracy task in which they watched videos of people discussing emotional events from their life and rated how they thought the people in the videos were feeling.
Although all participants were healthy adults who did not have autism, the researchers looked at whether differences in social cognitive expertise affected response to oxytocin.
Social competency was measured using the Autism Spectrum Quotient (AQ), a common self-report instrument that predicts social cognitive performance.
Researchers hypothesized that oxytocin and AQ would interact to predict social cognitive performance.
Results showed that oxytocin improved empathic accuracy, but only in those individuals who were less socially proficient.
"Oxytocin is widely believed to make all people more empathic and understanding of others. Our study contradicts that. Instead, oxytocin appears to be helpful only for those who are less socially proficient," said Dr. Jennifer Bartz, Assistant Professor, Psychiatry, Mount Sinai School of Medicine, and lead author of the study.
More socially proficient participants performed well on the empathic accuracy task regardless of whether they were on oxytocin or placebo.
On the other hand, less socially proficient participants performed poorly on placebo but significantly better on oxytocin.
In fact, on oxytocin, their empathic accuracy performance was identical to that of the socially proficient participants.
"Our data show that oxytocin selectively improves social cognition in people who are less socially proficient, but had little impact on more socially proficient individuals. While more research is required, these results highlight the potential oxytocin holds for treating social deficits in people with disorders marked by deficits in social functioning like autism," said Bartz.
Source: ANI
Advertisement
Although all participants were healthy adults who did not have autism, the researchers looked at whether differences in social cognitive expertise affected response to oxytocin.
Social competency was measured using the Autism Spectrum Quotient (AQ), a common self-report instrument that predicts social cognitive performance.
Researchers hypothesized that oxytocin and AQ would interact to predict social cognitive performance.
Results showed that oxytocin improved empathic accuracy, but only in those individuals who were less socially proficient.
"Oxytocin is widely believed to make all people more empathic and understanding of others. Our study contradicts that. Instead, oxytocin appears to be helpful only for those who are less socially proficient," said Dr. Jennifer Bartz, Assistant Professor, Psychiatry, Mount Sinai School of Medicine, and lead author of the study.
More socially proficient participants performed well on the empathic accuracy task regardless of whether they were on oxytocin or placebo.
On the other hand, less socially proficient participants performed poorly on placebo but significantly better on oxytocin.
In fact, on oxytocin, their empathic accuracy performance was identical to that of the socially proficient participants.
"Our data show that oxytocin selectively improves social cognition in people who are less socially proficient, but had little impact on more socially proficient individuals. While more research is required, these results highlight the potential oxytocin holds for treating social deficits in people with disorders marked by deficits in social functioning like autism," said Bartz.
Source: ANI
Advertisement
Advertisement
|
Advertisement
Recommended Reading
Latest Clinical Trials News

Amyotrophic lateral sclerosis patients' motor neurons responded robustly to Parkinson's drug ropinirole.

A new way to quickly eliminate fungal infections in the mouth has been developed by researchers at Penn Dental and Penn Engineering, using magnetically guided nanorobots.

Researchers tested the effectiveness of virus-mediated gene therapy for genetic hearing loss in an aged mouse model with genetic changes related to deafness.

The outcomes of the first clinical trial demonstrate the safety and efficacy of the measles-rubella (MR) vaccination to adults and infants as young as 9 months.

Scientists devise a fully integrated autonomous wearable ultrasonic-system-on-patch to sense deep tissue vital signs wirelessly even when the patient is on the move.